ImmunoGen (IMGN) Short Interest Ratio & Short Volume

Short interest is the volume of ImmunoGen shares that have been sold short but have not yet been covered or closed out. As of January 31st, traders have sold 20,610,000 shares of IMGN short. Learn More on ImmunoGen's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMGN shares currently have a short interest ratio of 2.0. Learn More on ImmunoGen's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of ImmunoGen: Prelude Capital Management LLC, Glazer Capital LLC, PEAK6 Investments LLC, DLD Asset Management LP, UBS Group AG, Picton Mahoney Asset Management, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

ImmunoGen saw a increase in short interest in January. As of January 31st, there was short interest totaling 20,610,000 shares, an increase of 9.3% from the previous total of 18,860,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to ImmunoGen: Roivant Sciences Ltd. (5.59%), RayzeBio, Inc. (2.32%), Crinetics Pharmaceuticals, Inc. (7.05%), Bio-Rad Laboratories, Inc. (2.87%), Ascendis Pharma A/S (5.75%), Penumbra, Inc. (4.99%), Encompass Health Co. (2.50%), Intra-Cellular Therapies, Inc. (3.58%), Qiagen (1.62%), Legend Biotech Co. (5.49%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.48 billion), General Motors ($3.85 billion), Charter Communications, Inc. ($3.38 billion), Occidental Petroleum Co. ($3.00 billion), Super Micro Computer, Inc. ($2.66 billion), Tractor Supply ($2.37 billion), Coinbase Global, Inc. ($2.25 billion), Moderna, Inc. ($2.11 billion), Royal Caribbean Cruises Ltd. ($2.06 billion), and Floor & Decor Holdings, Inc. ($1.67 billion). View all of the most shorted stocks.

Short selling IMGN is an investing strategy that aims to generate trading profit from ImmunoGen as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for ImmunoGen occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMGN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMGN, twice per month. The most recent reporting period available is January, 31 2024.